StreetInsider.com News Articles

Form 11-K THERMO FISHER SCIENTIFIC For: Dec 31

Tue, 23 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26679404.html

Form 11-K THERMO FISHER SCIENTIFIC For: Dec 31

Tue, 23 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26679404.html

Piper Sandler Starts Thermo Fisher Scientific (TMO) at Neutral

Thu, 11 Jun 2026 05:38:08 -0400

(Updated - June 11, 2026 5:38 AM EDT)

Piper Sandler analyst David Westenberg initiates coverage on Thermo Fisher Scientific (NYSE: TMO) with a Neutral rating and a price target of $510.00.

The analyst comments: “We initiate coverage of Thermo Fisher Scientific (TMO) with a Neutral rating and $510 PT. As the defining franchise in life science tools, we believe its growth is tied to the health and expansion of the broader life science tools market. Our Neutral rating reflects optimism of a recovery with a concern that the market might need new legs of growth. We think Thermo is large enough that

Piper Sandler Starts Thermo Fisher Scientific (TMO) at Neutral

Thu, 11 Jun 2026 05:38:08 -0400

(Updated - June 11, 2026 5:38 AM EDT)

Piper Sandler analyst David Westenberg initiates coverage on Thermo Fisher Scientific (NYSE: TMO) with a Neutral rating and a price target of $510.00.

HSBC Downgrades Thermo Fisher Scientific (TMO) to Hold

Wed, 03 Jun 2026 03:12:42 -0400

HSBC analyst Sidharth Sahoo downgraded Thermo Fisher Scientific (NYSE: TMO) from Buy to Hold with a price target of $540.00 (from $670.00).

The analyst comments: “We think Thermo’s narrative of getting back to 7% growth beyond 2027 needs more support. A lower exposure to Bioprocessing in comparison to sector peers and questions on outsourcing momentum / CDMO utilisation levels amidst large pharma capex make us nervous in the near term. Expectations continue to remain bearish. That said, Thermo’s scale and fully fledged tool offerings make the company one of the key beneficiaries of the greenfield capex in the US intended by

HSBC Downgrades Thermo Fisher Scientific (TMO) to Hold

Wed, 03 Jun 2026 03:12:42 -0400

HSBC analyst Sidharth Sahoo downgraded Thermo Fisher Scientific (NYSE: TMO) from Buy to Hold with a price target of $540.00 (from $670.00).

Wolfe Research Assumes Thermo Fisher Scientific (TMO) at Outperform

Mon, 01 Jun 2026 16:30:32 -0400

(Updated - June 1, 2026 4:30 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on Thermo Fisher Scientific (NYSE: TMO) with a Outperform rating and a price target of $535.00.

The analyst comments "We rate TMO shares Outperform and have a $535 target price. This represents a 20 P/E multiple applied to our 2027 EPS estimate. This input approximates the current sector multiple which means we price TMO at parity to the space overall. Relative to the S&P 500, a 20 P/E is a 5%-10% discount which is squarely bottom quartile of the last ~15-years and close to the ‘never lower’

Wolfe Research Assumes Thermo Fisher Scientific (TMO) at Outperform

Mon, 01 Jun 2026 16:30:32 -0400

(Updated - June 1, 2026 4:30 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on Thermo Fisher Scientific (NYSE: TMO) with a Outperform rating and a price target of $535.00.

Form 144 THERMO FISHER SCIENTIFIC Filed by: Lagarde Michel

Fri, 29 May 2026 12:14:00 -0400

si-local-file:///var/storage/secattach/20260529/26572753.html

Form 144 THERMO FISHER SCIENTIFIC Filed by: Lagarde Michel

Fri, 29 May 2026 12:14:00 -0400

si-local-file:///var/storage/secattach/20260529/26572753.html

Form SD THERMO FISHER SCIENTIFIC

Thu, 28 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260528/26568053.html

Form SD THERMO FISHER SCIENTIFIC

Thu, 28 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260528/26568053.html

Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies